<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699968</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1701-Ⅱ-206</org_study_id>
    <nct_id>NCT04699968</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC</brief_title>
  <official_title>Phase II Clinical Trial of SHR-1701 With or Without Famitinib in the Treatment of Advanced or Metastatic NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without&#xD;
      famitinib in patients with advanced or metastatic NSCLC&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1701 with or without Famitinib</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>determined by RECIST v1.1, up to approximately 1 year</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>determined by RECIST v1.1, up to approximately 1 year</time_frame>
    <description>Progression-Free-Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>determined by RECIST v1.1, up to approximately 1 year</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>determined by RECIST v1.1, up to approximately 1 year</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to approximately 1 year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs+ SAEs</measure>
    <time_frame>determined by NCI-CTCAE V5.0, from the first drug administration to within 90 days for the last SHR-1701 dose</time_frame>
    <description>Adverse Events and Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701，Famitinib</intervention_name>
    <description>SHR -1701, Intravenous ；Famitinib, oral</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701</intervention_name>
    <description>SHR -1701, Intravenous</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. voluntarily participate in the study and sign the informed consent form;&#xD;
&#xD;
          2. 18 to 75 years old, both male and female;&#xD;
&#xD;
          3. histologically or cytologically confirmed stage IIIB-IV or recurrent NSCLC&#xD;
&#xD;
          4. one prior platinum-containing chemotherapy for advanced or metastatic disease;&#xD;
&#xD;
          5. measurable lesions by RECIST v1.1;&#xD;
&#xD;
          6. ECOG score: 0-1;&#xD;
&#xD;
          7. life expectancy ≥ 3 months;&#xD;
&#xD;
          8. adequate hematological, hepatic and renal function;&#xD;
&#xD;
          9. non-surgically sterile female subjects of childbearing age must have a negative serum&#xD;
             HCG test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. histologically or cytologically confirmed mixed SCLC and NSCLC;&#xD;
&#xD;
          2. known sensitising EGFR mutation and/or ALK translocation in patients with non-squamous&#xD;
             NSCLC;&#xD;
&#xD;
          3. tumor infiltration into the great vessels on imaging;&#xD;
&#xD;
          4. active CNS metastases;&#xD;
&#xD;
          5. malignancies other than NSCLC within 5 years;&#xD;
&#xD;
          6. anticancer therapy within 4 weeks before the start of trial treatment;&#xD;
&#xD;
          7. persisting toxicity related to prior therapy of Grade &gt; 1;&#xD;
&#xD;
          8. treatment with systemic immunostimulatory agents within 4 weeks;&#xD;
&#xD;
          9. treatment with systemic immunosuppressive agents within 2 weeks;&#xD;
&#xD;
         10. autoimmune diseases;&#xD;
&#xD;
         11. interstitial lung disease or other lung diseases that is symptomatic or may interfere&#xD;
             the management of suspected drug-related pulmonary toxicity;&#xD;
&#xD;
         12. clinically significant cardiovascular or cerebrovascular diseases;&#xD;
&#xD;
         13. inadequately controlled hypertension;&#xD;
&#xD;
         14. history of hemoptysis (≥ 2.5mL of bright red blood per episode) within 1 month;&#xD;
&#xD;
         15. venous or arterial thrombosis within 6 months;&#xD;
&#xD;
         16. evidence of bleeding diathesis or coagulopathy;&#xD;
&#xD;
         17. use of anticoagulants or thrombolytic agents that has not been stable;&#xD;
&#xD;
         18. active Tuberculosis infection;&#xD;
&#xD;
         19. significant acute or chronic infections within 1 month;&#xD;
&#xD;
         20. known history of testing positive test for HIV or known AIDS;&#xD;
&#xD;
         21. hepatitis B virus or hepatitis C virus infection;&#xD;
&#xD;
         22. allergic to any component of the treatment regimen;&#xD;
&#xD;
         23. other conditions that in the opinion of the investigator would make participation in&#xD;
             this clinical trial inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Shi, M.D</last_name>
    <phone>+86 021-61053363</phone>
    <email>shiwei@hrglobe.cn</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

